Диссертация (1141381), страница 24
Текст из файла (страница 24)
The fluid mosaic model of the structure of cell membranes//Science. – 1972. – Т. 175. – №. 4023. – С. 720-731.226. Smith I. E. Mitoxantrone (novantrone): a review of experimental and early clinicalstudies //Cancer treatment reviews. – 1983. – Т. 10. – №. 2. – С. 103-115.227. Sorgi F. L., Huang L. Large scale production of DC-Chol cationic liposomes bymicrofluidization //International journal of pharmaceutics. – 1996. – Т. 144. – №. 2.
– С.131-139.228. Stathopoulos G. P., Boulikas T. Lipoplatin formulation review article //Journal of drugdelivery. – 2011. – Т. 2012.229. Synthesis of amino-substituted 9,10-antracenediones .- DDR Patent 290774 A7.-1987230. Synthesis of antineoplastic agent DHAQ.-DDR Patent 294389 A7.-1988.231. Szoka F., Papahadjopoulos D.
Procedure for preparation of liposomes with largeinternal aqueous space and high capture by reverse-phase evaporation //Proceedings of theNational Academy of Sciences. – 1978. – Т. 75. – №. 9. – С. 4194-4198.232. Szoka Jr F., Papahadjopoulos D. Comparative properties and methods of preparation oflipid vesicles (liposomes) //Annual review of biophysics and bioengineering. – 1980. – Т. 9.– №. 1.
– С. 467-508.233. The Merck Index, Centennial Edition.-1992, Mitoxantrone .-P.979.133234. Thompson A. K., Mozafari M. R., Singh H. The properties of liposomes produced frommilk fat globule membrane material using different techniques //Le Lait. – 2007. – Т. 87. –№. 4-5. – С. 349-360.235.
Torchilin V. Antibody-modified liposomes for cancer chemotherapy //Expert opinion ondrug delivery. – 2008. – Т. 5. – №. 9. – С. 1003-1025.236. Torchilin V. Multifunctional and stimuli-sensitive pharmaceutical nanocarriers//European Journal of Pharmaceutics and Biopharmaceutics. – 2009. – Т. 71. – №. 3.
– С.431-444.237. Torchilin V. P. et al. p-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and simpleattachment of specific ligands, including monoclonal antibodies, to distal ends of PEGchains via p-nitrophenylcarbonyl groups //Biochimica et Biophysica Acta (BBA)Biomembranes. – 2001. – Т. 1511. – №.
2. – С. 397-411.238. Torchilin V. P. et al. p-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and simpleattachment of specific ligands, including monoclonal antibodies, to distal ends of PEGchains via p-nitrophenylcarbonyl groups //Biochimica et Biophysica Acta (BBA)Biomembranes. – 2001. – Т. 1511. – №. 2. – С. 397-411.239. Torchilin V. P. Multifunctional nanocarriers //Advanced drug delivery reviews.
– 2012.– Т. 64. – С. 302-315.240. Torchilin V. P. Targeted pharmaceutical nanocarriers for cancer therapy and imaging//The AAPS journal. – 2007. – Т. 9. – №. 2. – С. E128-E147.241. Torchilin V., Weissig V. Liposomes: a practical approach. – Oxford University Press,2003. – №. 264. – С. 153.242. Torchilin V., Weissig V. Liposomes: a practical approach. – Oxford University Press,2003. – №. 264.243. Tulpule A. et al. Phase I/II trial of nonpegylated liposomal doxorubicin,cyclophosphamide, vincristine, and prednisone in the treatment of newly diagnosedaggressive non-Hodgkin's lymphoma //Clinical Lymphoma and Myeloma. – 2006.
– Т. 7. –№. 1. – С. 59-64.244. United States Pharmacopoeia XXMII, Rockville, 2003.- С.1034-1036.245. Van Zanten J. et al. A nonviral carrier for targeted gene delivery to tumor cells //Cancergene therapy. – 2004. – Т. 11. – №. 2. – С. 156-164.246. Vartanian A. A. et al. Melanoma vasculogenic mimicry is strongly related to reactiveoxygen species level //Melanoma research. – 2007. – Т. 17. – №. 6. – С.
370-379.247. Vartanian A. A. et al. Prognostic significance of periodic acid-Schiff-positive patterns inclear cell renal cell carcinoma //The Canadian journal of urology. – 2009. – Т. 16. – №. 4. –С. 4726-4732.248. Vartanian A. A. et al. The involvement of apoptosis in melanoma vasculogenic mimicry//Melanoma research. – 2007. – Т. 17. – №. 1.
– С. 1-8.249. Vartanian A. et al. VEGFR1 and PKCα signaling control melanoma vasculogenicmimicry in a VEGFR2 kinase-independent manner //Melanoma research. – 2011. – Т. 21. –№. 2. – С. 91-98.250. Vemuri S. et al. Large-scale production of liposomes by a microfluidizer //Drugdevelopment and industrial pharmacy. – 1990.
– Т. 16. – №. 15. – С. 2243-2256.251. Voinea M., Simionescu M. Designing of ‘intelligent’liposomes for efficient delivery ofdrugs //Journal of cellular and molecular medicine. – 2002. – Т. 6. – №. 4. – С. 465-474.252. Wang G. Acute effects of mitoxantrone on the electromechanical properties ofventricular myocardium : дис. – Universitätsbibliothek, 2000.253. Warren G. B. et al. Reversible lipid titrations of the activity of pure adenosinetriphosphatase-lipid complexes //Biochemistry. – 1974.
– Т. 13. – №. 27. – С. 5501-5507.254. Wasserman V. et al. The antioxidant tempamine: in vitro antitumor and neuroprotectiveeffects and optimization of liposomal encapsulation and release //Langmuir. – 2007. – Т.23. – №. 4. – С. 1937-1947.134255. Weiner A. L. Chemistry and biology of immunotargeted liposomes //Targeted diagnosisand therapy. – 1990.
– Т. 3. – С. 305.256. Woodbury D. J. et al. Reducing liposome size with ultrasound: bimodal sizedistributions //Journal of liposome research. – 2006. – Т. 16. – №. 1. – С. 57-80.257. Woodle M. C., Lasic D. D. Sterically stabilized liposomes //Biochimica et BiophysicaActa (BBA)-Reviews on Biomembranes. – 1992. – Т. 1113. – №. 2. – С. 171-199.258. Woodle MC, Papahadjopoulos D.
Liposome preparation and size characterization.1997. Academic Press, INC, San Diego; 1997259. Wu H. C., Chang D. K., Huang C. T. Targeted therapy for cancer //J Cancer Mol. –2006. – Т. 2. – №. 2. – С. 57-66.260. Wu Y. L. et al. INSPIRE: a phase III study of the BLP25 liposome vaccine (L-BLP25)in Asian patients with unresectable stage III non-small cell lung cancer //BMC cancer. –2011. – Т. 11.
– №. 1. – С. 1.261. XXIV U. S. P. United States Pharmacopoeial Convention //Inc: Rockville, MD. – 2006.– Т. 20001943.262. Yarmolenko P. S. et al. Comparative effects of thermosensitive doxorubicin-containingliposomes and hyperthermia in human and murine tumours //International Journal ofHyperthermia. – 2010. – Т.
26. – №. 5. – С. 485-498.263. Yuan F. et al. Mirovascular permeability and interstitial penetration of stericallystabilized (stealth) liposomes in a human tumor xenograft //Cancer research. – 1994. – Т.54. – №. 13. – С. 3352-3356.264. Zee-Cheng R. K. Y., Cheng C. C. Antineoplastic agents. Structure-activity relationshipstudy of bis (substituted aminoalkylamino) anthraquinones //Journal of medicinalchemistry. – 1978. – Т.
21. – №. 3. – С. 291-294.265. Zhang J. A. et al. Development and characterization of a novel Cremophor® EL freeliposome-based paclitaxel (LEP-ETU) formulation //European journal of pharmaceutics andbiopharmaceutics. – 2005. – Т. 59. – №. 1. – С. 177-187.266. Zhang Y. P., Čeh B., Lasic D. D. Liposomes in drug delivery. – 2002.135ПРИЛОЖЕНИЯПриложение 1.136137138Приложение 2.139140141Приложение 3.142143Приложение 4.144Приложение 5. Технологическая схема получения ИЛЛФ митоксантрона.145Приложение 6. Технологическая схема получения ЛЛФ митоксантрона..
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
